Product
Feature
Quick Research
Generate reliable direction feasibility study reports for your R&D in just a few steps.
Technical Q&A
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
Find Solutions
As an expert in R&D theories, this can generate solutions to your technical problems instantly.
Evaluate Feasibility
Analyze your overall solution with one click, know your potential R&D risks in advance.
Monitor Landscape
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
122 results about "Anti atherosclerotic" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
InactiveUS20050181451A1Easy to detectDelay disease progressionDisease diagnosisBiological testingCoronary arteriesCoronary Artery Disease Symptoms
A method of assessing the likelihood that a person who is asymptomatic for coronary artery disease does in fact have the disease is disclosed. The levels of an atherogenic protein and acute phase reactant and optionally of anti-atherogenic protein for an individual are obtained and compared to one or more cut-points related to those substances and, based on the comparison(s), an assessment is made of the likelihood that the individual has coronary artery disease. The atherogenic protein may be OxLDL, the acute phase reactant may be C-reactive protein or fibrinogen, and the anti-atherogenic protein may be HDL.
Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an Anti-atherosclerotic drug
The invention provides a method for determining if a subject has atherosclerosis, including: determining an endogenous microRNA-195 expression level of a subject suspected of having atherosclerosis; and comparing the endogenous microRNA-195 expression level of the subject with an endogenous microRNA-195 expression level of a normal group, wherein an increase in the endogenous microRNA-195 expression level of the subject as compared to the endogenous microRNA-195 expression level of the normal group indicates that the subject has atherosclerosis.
Owner:KAOHSIUNG MEDICAL UNIVERSITY
Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof
ActiveUS20090074663A1Ultrasonic/sonic/infrasonic diagnosticsPeptide/protein ingredientsAtheromaAnti atherosclerotic
A peptide for diagnosing, preventing and treating atherosclerosis, and a use thereof, comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and a use thereof. The peptide effectively targets atherosclerotic plaques, and binds to IL-4R to thereby exhibit antagonistic effects on IL-4-mediated signaling of cellular inflammatory reaction and survival reaction. The peptide of the present invention can be used for diagnosis of atherosclerosis, prevention and treatment of IL-4-induced inflammatory reaction and prevention and treatment of atherosclerosis which is primarily caused by the inflammatory reaction, as well as for prevention or treatment of atherosclerosis via conjugation with an anti-atherosclerotic drug.
Owner:KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND
[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis
The instant invention provides compounds of Formula (I) which are leukotriene biosynthesis inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
![[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis](https://images-eureka.patsnap.com/patent_img/e807bd41-5a7a-43a5-8d6d-71607587208f/A2008800112240119H1.PNG "[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis")
![[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis](https://images-eureka.patsnap.com/patent_img/e807bd41-5a7a-43a5-8d6d-71607587208f/A2008800112240120H1.PNG "[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis")
![[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis](https://images-eureka.patsnap.com/patent_img/e807bd41-5a7a-43a5-8d6d-71607587208f/A2008800112240121H1.PNG "[1,2,3] triazolyl substituted quinolines and coumarins as inhibitors of leukotriene biosynthesis")
Owner:MERCK CANADA
Optically active butylphthalide open-ring derivative, preparation method and medical application
InactiveCN103193789AFuzzy structureReduce the numberNervous disorderOrganic chemistryDiseaseAntithrombotic Agent
The present invention relates to the field of pharmaceutical chemistry and therapeutics, and particularly relates to an optically active butylphthalide open-ring derivative as shown in the general formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, preparation methods thereof, pharmaceutical compositions containing the compounds, and medical application thereof, especially application in medicines for prevention and treatment of cardiovascular and cerebrovascular and improvement of heart and brain circulatory disturbance, antiplatelet aggregation medicines, antithrombotic medicines, anti-ischemic medicines, anti-dementia medicines, anti-atherosclerotic medicines, and medicines for anti-diabetes and complications thereof. Pharmacological experimental results show that the compounds have good anti-platelet aggregation activity, anti-thrombotic activity, anti-ischemic activity and neuroprotective effects, and are clinically useful for the preparation of medicines for preventing or treating diseases associated with platelet aggregation.
Owner:CHINA PHARM UNIV
Methods of treating atherosclerosis
InactiveUS20110190324A1Preventing and slowing progression of atherosclerotic plaque build-upAvoid attackOrganic active ingredientsBiocideAdenosine A3 Receptor AntagonistsAtheroma
The present invention relates to adenosine A3 receptor antagonists and their use for the prevention and treatment of atherosclerosis by administering to a mammal, in need thereof, a therapeutically effective amount of an adenosine A3 receptor antagonist, or a pharmaceutically acceptable salt thereof, alone or in combination with other anti-atherosclerotic agents.
Owner:KING PHARMA RES & DEV +6
Functional protein powder containing conjugated linoleic acid glycerides
The invention relates to the technical field of functional food, in particular to a functional protein powder containing conjugated linoleic acid glycerides. The formula of the functional protein powder comprises 50 to 88 parts of soybean isolated protein powder, 5 to 30 parts of whey protein powder, 3 to 20 parts of conjugated linoleic acid glyceride microcapsule powder and 1 to 10 parts of powder phospholipid. The conjugated linoleic acid glyceride composition added in the formula not only can be used for reducing cholesterol and resisting the atherosis so as to be favorable for reducing the blood fat, but also has a function for improving the immunity, improving the nutritive allocation and controlling the weight. A functional food with multiple healthcare functions for preventing and improving affluence illnesses can be provided for people with overnutrition or having the risk of overnutrition along the rising living standard.
Owner:GUANGDONG APOLLO GRP
Medical combination including rhein or diacetylrhein and the preparing method thereof
The present invention relates to one kind of medicine composition containing rheinic acid or diacetyl rheinic acid and its pharmaceutically acceptable salt, dispersant carrier material and other supplementary material. The medicine composition is prepared through a melting process, a solvent process, a melting-solvent process or a fine grinding process to prepare effective component dispersoid; and further dropping the dispersoid into condensing agent to prepare dripping pill, or other steps to prepare different other preparations. The medicine composition of the present invention has raised bioavailability, and may be applied widely in treating osteoarthritis, rheumatoid arthritis, hyperlipemia and other diseases.
Owner:刘德海
Beta-elemene 13-site derivative and use thereof in treatment of atherosclerosis
InactiveCN104130124ASame medicinal effectOrganic compound preparationCarboxylic acid esters preparationOrganic synthesisAnti atherosclerosis
The invention relates to the field of organic synthesis and medicinal chemistry, and in particular relates to a beta-elemene 13-site derivative (I) or (II), and R1 and R2 are as defined in specification. The invention also discloses a preparation method of the beta-elemene 13-site derivative and use thereof in anti atherosclerosis.
Owner:DALIAN YUANDA PHARMA TECH DEV
Medicinal composition containing rosuvastatin or pitavastatin and B clan vitamin
ActiveCN1891219AGood curative effectImprove compliancePill deliveryGranular deliveryDiseasePitavastatin
The present invention relates to a medicine composition conlaining resulvatatine or pivatatine compound and vitamins B, in which the resulvatatine or pivatatine content is 1-40 mg and vitamins B content is 0.1-50 mg. Said invention also provides the application of said medicine composition in preparation of medicine for preventing and curing the diseases of atherosclerosis, angiocardiopathy and cerebrovascular disease.
Owner:SHENZHEN AUSA PHARM CO LTD
Method for synthesis of N-homocysteine thiolactonyl retinamide
InactiveUS6054595AEasily removable by washingImprove responseOrganic chemistryOrganic synthesisN-homocysteine thiolactonyl retinamide
The present invention describes a method of organic synthesis for N-homocysteine thiolactonyl retinamide, a compound that has anticancer and antiatherogenic properties.
Owner:BAYLOR UNIVERSITY
Preparation and application of triterpene drug for inhibiting synthesis and secretion of apoB48 in intestinal tracts
The invention relates to the field of pharmacy, and specifically relates to the preparation and application of a drug. The drug is prepared from triterpene compounds, which are purchased or extracted from cyclocarya paliurus, and is used to inhibit the synthesis and secretion of apoB48 in the intestinal tracts. The invention especially discloses applications of triterpene compounds in the preparation of drugs for preventing hyperlipidemia, cardiovascular and cerebrovascular diseases, and atherosis. The invention further discloses a series of triterpene compounds and the preparation and applications thereof in the preparation of drugs for inhibiting the synthesis and secretion of apoB48 in intestinal tracts.
Owner:CHINA PHARM UNIV
Medicine for treating and preventing ischemic cardiovascular and cerebrovascular diseases
InactiveCN102626476ASignificant clinical effectImprove heart and brain functionCardiovascular disorderLeech/worm material medical ingredientsDiseaseSecondary Preventions
The invention discloses a medicine for treating and preventing ischemic cardiovascular and cerebrovascular diseases, which belongs to the field of traditional Chinese medicine and is composed of the following bulk pharmaceutical chemicals by weight: 3-5 parts of Astragalus mongholicus, 3-5 parts of suncured ginseng, 2-10 parts of rheum officinale, 3-5 parts of leeches, 3-5 parts of radix notoginseng, 2-3 parts of Ligusticum wallichii, 3-5 parts of radix salviae miltiorrhizae, 2-10 parts of the root of kudzu vine, 2-3 parts of corydalis tuber and 1-2 parts of dragon's blood. By proportioning the bulk pharmaceutical chemicals, the medicine has the functions of tonifying qi, activating blood circulation and removing stasis, resisting atherosclerosis and resisting thrombopoiesis. The medicine has the advantages of being used in treating, primary prevention, secondary prevention and tertiary prevention of ischemic cardiovascular and cerebrovascular diseases and achieving good clinical effects. Condition of patients is stable, and the diseases can no longer occur, heart and brain functions are obviously improved, lift quality is obviously improved, and patients with light illness can return back to work.
Owner:周长勤
Cordyceps militaris sporocarp heteropolysaccharide and application thereof
ActiveCN105585639AReduce savingsAnti-atherosclerotic effectMetabolism disorderCardiovascular disorderArcus aortaeFreeze-drying
The invention discloses a preparation method and application of cordyceps militaris sporocarp heteropolysaccharide. The preparation method mainly comprises the following steps that cordyceps militaris sporocarp is subjected to drying, pulverization, ethanol degreasing and hot water ultrasonic extraction, and an extracting solution is subjected to concentration, alcohol precipitation, deproteinization, column chromatography, dialysis and freeze-drying, so that the cordyceps militaris sporocarp heteropolysaccharide TY258 is obtained. The cordyceps militaris polysaccharide has the efficacy of lowering lipid and resisting to atherosclerosis and can remarkably lower the cholesterol level, the triglyceride level and the low density lipoprotein level of high-fat induced atherosclerosis model mice (mice with apolipoprotein and low density lipoprotein receptors knocked out) and lipid accumulation of the livers and arcus aortae at the concentration of 25 mg / kg, lift the high density lipoprotein cholesterol level of the mice and improve activity of superoxide dismutase and lipoprotein esterolysis enzyme. The cordyceps militaris sporocarp polysaccharide can also remarkably lower the contents of plasma triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein of high-fat induced guinea pigs and rats.
Owner:TAISHAN MEDICAL UNIV
Medicine for resisting atherosclerotic inflammation and anti-inflammatory effect detection method
PendingCN111789835APrevent proliferationInhibit migrationCompounds screening/testingOrganic active ingredientsProtein targetVasculitis
The invention belongs to the technical field of atherosclerotic targeted drugs, and discloses a medicine for resisting atherosclerotic inflammation and an anti-inflammatory effect detection method, and the medicine for resisting atherosclerotic inflammation is artesunate. The method for detecting the anti-inflammatory effect of the medicine for resisting atherosclerotic inflammation comprises thefollowing steps: performing an in-vitro experiment of using ox-LDL to induce VSMC phenotype to be converted into inflammatory phenotype cells; performing an in vivo experiment of using ox-LDL to induce VSMC phenotype to be converted into inflammatory phenotype cells. According to the invention, a molecular biology method is adopted, and the artesunate and target protein NLRP3 binding target is comprehensively investigated through a cell model and an animal model for inhibiting ox-LDL from inducing phenotypic transformation of VSMCs inflammatory cells by artesunate; and the anti-inflammatory effect and the molecular mechanism of artesunate in AS vascular inflammatory injury are illustrated by inhibiting the anti-inflammatory effect and the molecular mechanism of ox-LDL induced VSMCs inflammatory cell phenotypic transformation.
Owner:ZUNYI MEDICAL UNIVERSITY
PH-sensitive hyaluronic acid nano drug-loading particles targeting atherosclerosis and preparation method thereof
InactiveCN110354095AImprove stabilityPrecise positioningPharmaceutical non-active ingredientsMicrocapsulesHydrazine compoundCD44
Owner:SOUTHEAST UNIV
Use of beta-elemene and derivatives thereof in preventing atherosclerosis
The invention relates to the field of natural medicines, and particularly relates to use of beta-elemene and derivatives thereof in preventing atherosclerosis, and in particular relates to an application in preparation of medicines for treating atherosclerosis. Test results show that beta-elemene and derivatives can remarkably reduce the atherosclerotic plaque area in the coronary artery of an animal model, and meanwhile has remarkable improving effect on two key links in development process of atherosclerosis: adhesion of leukocyte and endothelial cells and peroxidation of lipids. Expression of adherence factors closely related to atherosclerosis can be reduced, so that peroxidation damage of endothelial cells in vitro and in vivo caused by high fat and H2O2 is avoided.
Owner:DALIAN YUANDA PHARMA TECH DEV
Minimal molecule RNA-155 having medical purpose of antiatherosclerotic
InactiveCN102188441AGood inhibitory effectEnhanced inhibitory effectOrganic active ingredientsPowder deliveryMedicineOrganism
The invention provides a miRNA-155 used to prepare an antiatherosclerotic medicine. Trough experiments, it is proved in the invention that miRNA-155 has a substantial inhibition effect towards atherosclerotic inflammation no matter on the external cell level or on the internal atherosclerotic module mice level. Because miRNA-155 is a regulation and control molecule in the upstream of genes and simultaneously possesses a plurality of biology functions, so it is very likely that miRNA-155 can become a brand new target point of atherosclerotic treatment. The medicine provided in the invention can effectively prevent nucleic acid from being degraded in organisms, efficiently take an effect on a target organism and can be prepared into compound preparations with other known drugs treating atherosclerotic inflammation such as statins fat-adjusting drug and the like.
Owner:ZHEJIANG UNIV
Pharmaceutical composition containing clopidogrel and pharmaceutically acceptable salts thereof and preparation method of pharmaceutical composition
The invention relates to a compound composition preparation, as well as a preparation method and a use thereof, and particularly relates to a pharmaceutical composition taking clopidogrel and pharmaceutically acceptable salts thereof, as well as atorvastatin calcium as active ingredients, and the preparation method of the pharmaceutical composition. The pharmaceutical composition can be used for preventing and treating cardiovascular and cerebrovascular diseases and performing anti-atherosclerotic and anti-thrombotic treatment, and can further improve the single treatment effect of the clopidogrel and realize the synergy. After the pharmaceutical composition disclosed by the invention is used for preparing a pharmaceutical preparation, the compliance of a patient can be improved.
Owner:北京博时安泰科技发展有限公司
Antioxidant compound having anti atherosclerotic effect and preparation thereof
ActiveUS9580452B2Increased phosphorylationsAttenuated Ang-II-induced atherosclerosisPhosphorous compound active ingredientsPhosphorus organic compoundsBlood vesselAnti atherosclerotic
Owner:COUNCIL OF SCI & IND RES
Application of penthorum chinense pursh and compounds thereof in preparation of drugs for alleviating Alzheimer disease
PendingCN112807334AAlleviate Alzheimer's diseaseOrganic active ingredientsNervous disorderDiseasePharmaceutical drug
The invention discloses application of an extract of a traditional Chinese medicine penthorum chinense pursh in preparation of drugs for alleviating Alzheimer disease. The extract plays a role by inducing autophagy, and four key compounds in the extract are disclosed. The extract of penthorum chinense pursh and the compounds thereof show an anti-atherosclerosis oxidative stress injury effect in-vivo and in-vitro experiments, have an inhibitory effect on the formation of beta-amyloid protein fibers and the expression of Tao protein which cause Alzheimer disease, and have potential application in alleviating Alzheimer disease.
Owner:THE AFFILIATED HOSPITAL OF SOUTHWEST MEDICAL UNIV
Exogenous hydrogen sulfide donor, and preparation and application thereof
InactiveCN106928208ARelease stabilityPrecise control of contentOrganic active ingredientsOrganic chemistryHuman umbilical vein endothelial cellTherapeutic action
The invention provides an exogenous hydrogen sulfide donor, and discloses a therapeutic action of an anethol trithione derivative used as the exogenous hydrogen sulfide donor on cardiovascular diseases. The exogenous hydrogen sulfide donor can release hydrogen sulfide, can promote the growth of an HUVEC (human umbilical vein endothelial cell) atherosclerosis cell model, has an antiatherosclerotic effect, and hopefully becomes a new target drug researched and developed by drugs with antiatherosclerotic effects.
Owner:川北医学院
In-vitro foam cell formation model and application thereof in asymptomatic carotid atherosclerosis study
InactiveCN107629997AEasy to operateShort preparation timeBioreactor/fermenter combinationsBiological substance pretreatmentsCarotid atherosclerosisAtheroma
The invention discloses an in-vitro foam cell formation model and application thereof in asymptomatic carotid atherosclerosis study. A construction method of the foam cell formation model provided bythe invention comprises the following steps: sequentially culturing, from bottom to top, smooth muscle cells, endothelial cells and mononuclear cells in a cell culture device capable of performing mechanical stretching so as to obtain a multi-cell co-culture system; treating the multi-cell co-culture system by utilizing a low density lipoprotein, applying a tension effect to induce formation of foam cells by virtue of the cell culture device capable of performing mechanical stretching, thus obtaining the foam cell formation model during early occurrence of asymptomatic carotid atherosclerosis.According to the method disclosed by the invention, consumption of an animal model can be reduced, expenditure is saved, an economic and high-efficiency in-vitro screening model is provided for carotid atherosclerosis resistant new drug screening, and the in-vitro foam cell formation model has the advantages of being simple in preparation method, convenient in experimental operation, low in timeconsumption and stable in performance.
Owner:UNIVERSITY OF CHINESE ACADEMY OF SCIENCES
Ginger and garlic enteric-coated tablet and preparation method thereof
ActiveCN102961713AReasonable production processHigh active ingredientAntibacterial agentsPharmaceutical delivery mechanismBiotechnologyAntimicrobial action
The invention provides a ginger and garlic enteric-coated tablet and a preparation method thereof. The ginger and garlic enteric-coated tablet is prepared from ginger and garlic essence as raw materials by a beta-cyclodextrin inclusion process, has broad-spectrum antibacterial action, and also the functions of reducing blood fat and blood sugar, resisting atherosclerosis, resisting tumor, improving the organism immunity, and the like, and is high in technical content, high in inclusion rate, accurate in product drug release position, and high in bioavailability, so that the medicine is high in effective ingredient content, and strong in antibacterial action, thus overcoming the shortcomings that the previous product is low in effective ingredient content, has unpleasant odor, is inconvenient to carry and the like, and ensuring the quality of the product.
Owner:江西中天医药生物有限公司
Small peptide and application thereof
ActiveCN106749525ADysregulated proliferationRegulation of apoptosisPeptide/protein ingredientsMetabolism disorderSmooth muscleSmall peptide
The invention provides a small peptide and application thereof, and relates to the technical field of biology. The amino acid sequence of the small peptide is shown as SEQ ID NO:1. The invention also provides the application of the small peptide to preparation of functional food for alleviating diabetic complications, anti-atherosclerosis functional food, antioxidant functional food, a free radical scavenging product and a lipid peroxidation inhibition product. The small peptide not only has relatively high antioxidant capability, but also can be used for regulating high glucose-induced abnormal proliferation of VSMCs (vascular smooth muscle cells) and regulating apoptosis of the VSMCs in a high glucose environment to finally make the VSMCs tending to get normal, and thus has a broad development prospect on the aspects of prevention of atherosclerosis formation in the high glucose environment, alleviation of other diabetic complications and the like.
Owner:NANJING UNIV OF FINANCE & ECONOMICS
Medicine composition and application of medicine composition to preparing medicines for preventing and treating atherosclerosis and dyslipidemia
ActiveCN104983737AReduce MDA contentRegulate metabolismOrganic active ingredientsMetabolism disorderAnti atheroscleroticKnockout mouse
The invention discloses a medicine composition and application of the medicine composition to preparing medicines for preventing and treating atherosclerosis, dyslipidemia and related diseases. Flavonoids compounds and sialic acid N-acetylneuraminic acid are combined to be applied to an atherosclerotic model apoprotein-carried knockout mouse. Through the experimental study, it is found that the medicine composition can obviously adjust lipid metabolism, reduce the content of triglyceride, cholesterol, malonaldehyde and oxidized low-density lipoprotein in plasmas, improve the activity of superoxide dismutase and lipoprotein esterase of the high-fat-induced arterial model mouse (apoprotein-carried knockout mouse), reduce lipid deposition of the lipid in the liver and the arcus aortae of the apoprotein-carried knockout mouse, relieve the aortic disease conditions, and obtain the unexpected curative effect of the cooperativity atherosclerosis.
Owner:TAISHAN MEDICAL UNIV
Rny-derived small rnas as biomarkers for atherosclerosis-related disorders
ActiveUS20160237500A1Reduce riskNegative correlationHydrolasesPeptide/protein ingredientsDrugRelated disorder
The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2
Furoxan NO donor-type statin derivative and preparation method thereof
ActiveCN110128368AGood treatment effectAvoid the problem of mismatching mechanism of actionOrganic chemistryCardiovascular disorderChemical synthesisCoumaric acid
The invention discloses a furoxan NO donor-type statin derivative and a preparation method thereof, and belongs to the technical field of medicinal chemical synthesis. The derivative has the structural formula represented by the following formula: wherein R is an alkyl, R1 is a statin residual group, and R2 is an aryl or an aryl sulfonyl. A statin drug is selected to "hybridize" with a NO donor, both NO and the statin drug have good therapeutic effects on atherosclerosis, and the problem of the mismatch of action mechanisms of NO and the statin drug is effectively avoided. In addition, 4-coumaric acid is selected as a linking group, and thus the therapeutic effect of the drug can be effectively enhanced. The compound can effectively release NO in vitro, and the useful attempt for the development of NO donor anti-atherosclerosis drugs is made.
Owner:CHENGDU UNIV
Kit for detecting anti-atherosclerosis drugs in blood plasma through ultra-high performance liquid chromatography-tandem mass spectrometry
The invention discloses a kit for detecting anti-atherosclerosis drugs in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology, and belongs to the technical field of blood plasma detection. The kit aims at common anti-atherosclerosis medicines such as atorvastatin, o-hydroxy atorvastatin, p-hydroxy atorvastatin, rosuvastatin and digoxin. The kitdisclosed by the invention adopts an LC-MS / MS method, can be used for detecting the anti-atherosclerosis drugs at one time, and can be used for simultaneously monitoring a target drug and a metabolite; the kit is high in sensitivity and good in accuracy, can be well applied to clinical application, and provides a reliable basis for combined medication research of the blood plasma atherosclerosis-resistant drug.
Owner:NANJING PINSHENG MEDICAL TECH CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com